The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages

  Tada, Yoshifumi ^a   Ono, Nobuyuki ^a   Suematsu, Rie ^a   Tashiro, Satoko ^a   Sadanaga, Yuri ^a   Tokuda, Yukiko ^a   Ono, Yukihide ^a   Nakao, Yoshinobu ^a   Maruyama, Akihito ^a   Ohta, Akihide ^b   Koarada, Syuichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Abatacept; Foxp3; Ror t; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; ANTIRHEUMATIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RORC PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; ARTICLE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOXP3 GENE; GATA3 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; REAL TIME POLYMERASE CHAIN REACTION; RETINOIC ACID RECEPTOR RELATED ORPHAN RECEPTOR GAMMA TAU GENE; RHEUMATOID ARTHRITIS; RNA ANALYSIS; T BET GENE; T LYMPHOCYTE; AGED; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH17 CELL;

ABATACEPT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; HUMANS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84978389803     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1137-1     Document Type: Article

References (35)

1. McInnes IB, Schett G. The pathogensis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.
2. Moreland L, Bate G, Kirkpatrick P. Abatecept. Nat Rev Drug Discov. 2006;5:185-6.
3. Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830-5.
4. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology. 2009;48:602-6.
5. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 2007;56:2111-5.
6. Shahrara S, Huang Q, Mandelin II AM, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10:R93.
7. Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology. 2015;54:768-75.
8. Cooles FAH, Isaacs JD, Anderson AE. Treg cells in rheumatoid arthritis: An update. Curr Rheumatol Rep. 2013;13:352.
9. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2499-503.
10. Guggino G, Giardina AR, Raimondo S, Giardina G, Sireci G, Dieli F, et al. Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion. Clin Exp Rheumatol. 2014;32:77-81.
11. Pesce B, Soto L, Sabugo F, Wurmann P, Cuchacovich M, López MN, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171:237-42.
12. low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther. 2015;17:10.
13. Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L, Juárez-Reyes A, Monsiváis-Urenda A, Baranda L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol. 2011;31:588-95.
14. Pieper J, Herrath J, Raghavan S, Muhammad K, van Vollenhoven R, Malmström V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003;4:330-6.
16. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-33.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.
19. Scarsi M, Zanotti C, Chiarini M, Imberti L, Piantoni S, Frassi M, et al. Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol. 2014;32:204-10.
20. Picchianti Diamanti A, Rosado MM, Scarsella M, Germano C, Giorda E, Cascioli S, et al. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents. Clin Exp Immunol. 2014;177:630-40.
21. Thiolat A, Semerano L, Pers YM, Biton J, Lemeiter D, Portales P, et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014;66:273-83.
22. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54:1122-31.
23. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7-13.
24. Bettelli E, Carrier Y, Gao W, Korn T, Storm TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-8.
25. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A. 2009;106:8635-40.
26. Valmori D, Raffin C, Raimbaud I, Ayyoub M. Human RORgt + Th17 cells preferentially differentiate from naive FOXP3+ Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci U S A. 2010;107:19402-7.
27. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62-8.
28. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271-5.
29. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231-4.
30. McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 2012;64:3129-38.
31. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008;105:19396-401.
32. Ehrenstein MR, Evans JG, Singh A, Moore S, Wames G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med. 2004;200:277-85.
33. Ellis SD, McGovern JL, van Maurik A, Howe D, Ehrenstein MR, Notley CA. Induced CD8 + Foxp3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86. Arthritis Rheumatol. 2014;66:2694-705.
34. Guo Y, Zhang X, Qin M, Wang X. Changes in peripheral CD19(+) Foxp3(+) and CD19(+)TGFβ(+) regulatory B cell populations in rheumatoid arthritis patients with interstitial lung disease. J Thorac Dis. 2015;7:471-7.
35. Wang T, Sun X, Zhao J, Zhang J, Zhu H, Li C, et al. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. Ann Rheum Dis. 2015;74:1293-301.